Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | DRD4 | P21917 | 8/20 | 0.40 |
| ▸ | DRD3 | P35462 | 8/20 | 0.40 |
| ▸ | DRD1 | P21728 | 4/20 | 0.40 |
| ▸ | DRD5 | P21918 | 4/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143580 | 0.67 | DRD2 (0.52) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL21590356 | 0.64 | DRD3 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL576035 | 0.63 | CA2 (0.50) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL22444698 | 0.63 | DRD2 (0.57) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL12356798 | 0.62 | DRD2 (0.40) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL19462629 | 0.61 | CHRM1 (0.41) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL3128608 | 0.61 | DRD2 (0.61) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10181619 | 0.61 | DRD2 (0.51) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL19482466 | 0.61 | SLC6A4 (0.40) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1424672 | 0.60 | DRD2 (0.46) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-1957489-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | CYP11B1, CYP11B2, REN | DRD2 1945/4885DRD4 1633/4885DRD3 1075/4885 |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | REN, CYP11B1, CYP11B2 | DRD2 2652/4885DRD4 2513/4885DRD3 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.